Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29123731 | 1.00 | PTPRC (0.52) | PTPRCSLC7A5PTPN1PTGS1ITGB3 | |
| SCHEMBL29631978 | 0.97 | PTPRC (0.50) | PTPRCSLC7A5PTPN1PTGS1ITGB3 | |
| SCHEMBL273663 | 0.88 | PTPRC (0.57) | PTPRCSLC7A5PTPN1PTGS1ITGB3 | |
| SCHEMBL3626587 | 0.88 | PTPRC (0.57) | PTPRCSLC7A5PTPN1PTGS1ITGB3 | |
| SCHEMBL1152 | 0.88 | PTPRC (0.57) | PTPRCSLC7A5PTPN1PTGS1ITGB3 | |
| SCHEMBL4066744 | 0.88 | PTPRC (0.57) | PTPRCSLC7A5PTPN1PTGS1ITGB3 | |
| SCHEMBL19615883 | 0.87 | PTPRC (0.56) | PTPRCSLC7A5PTPN1PTGS1ITGB3 | |
| Phosphoric Acid SCHEMBL3476886 | 0.87 | PTPRC (0.56) | PTPRCSLC7A5PTPN1PTGS1ITGB3 | |
| SCHEMBL29567635 | 0.87 | PTPRC (0.56) | PTPRCSLC7A5PTPN1PTGS1ITGB3 | |
| SCHEMBL29613927 | 0.87 | PTPRC (0.56) | PTPRCSLC7A5PTPN1PTGS1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0596024-A4 | LIPID CONJUGATES OF THERAPEUTIC PEPTIDES AND PROTEASE INHIBITORS. | VESTAR INC (US) | 1996-07-17 | — | — | EP | claimed |
| EP-0596024-A1 | LIPID CONJUGATES OF THERAPEUTIC PEPTIDES AND PROTEASE INHIBITORS | NeXstar Pharmaceuticals, Inc. (US) | 1994-05-11 | — | — | EP | claimed |
| WO-1993001828-A1 | LIPID CONJUGATES OF THERAPEUTIC PEPTIDES AND PROTEASE INHIBITORS | VICAL, INC. (US) | 1993-02-04 | — | — | WO | claimed |
| US-20230219946-A1 | PYRIMIDIN-4(3H)-ONE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| EP-4092024-A1 | PYRIMIDINE-4(3H)-KETONE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE AND PHARMACOLOGY | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2022-11-23 | — | — | EP | disclosed |
| CN-114981268-A | Pyrimidine-4 (3H) -ketone heterocyclic compound, preparation method and application thereof in medicine and pharmacology | 北京诺诚健华医药科技有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-111393459-B | SHP2 inhibitor and application thereof | 南京安纳康生物科技有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20210154190-A1 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | Revolution Medicines, Inc. | 2021-05-27 | — | — | US | disclosed |
| EP-3773590-A1 | SHP2 INHIBITOR COMPOSITIONS, METHODS FOR TREATING CANCER AND METHODS FOR IDENTIFYING A SUBJECT WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-111393459-A | SHP2 inhibitor and application thereof | 南京安纳康生物科技有限公司 | 2020-07-10 | — | — | CN | disclosed |
| WO-2019199792-A1 | SHP2 INHIBITOR COMPOSITIONS, METHODS FOR TREATING CANCER AND METHODS FOR IDENTIFYING A SUBJECT WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2019-10-17 | — | — | WO | disclosed |
| US-20030055018-A1 | Modulation of phosphoinositide 3-kinase activity | THOMAS JEFFERSON UNIVERSITY | 2003-03-20 | — | — | US | disclosed |
| WO-2003006487-A2 | MODULATION OF PHOSPHOINOSITIDE 3-KINASE ACTIVITY | THOMAS JEFFERSON UNIVERSITY (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154190-A1 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | PTPN1, PTPN18, PTPN7 | PTPRC 18/4885SLC7A5 4623/4885PTPN1 1/4885 |
| US-20230219946-A1 | PYRIMIDIN-4(3H)-ONE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | PTPN5, PTPN1, JAK2 | PTPRC 21/4885SLC7A5 2267/4885PTPN1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.